Which has higher earnings & valuation, ZYXI or CODX?

Zynex has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A Co-Diagnostics $620K 19.75 -$46.90M -$15.77 N/A

Is ZYXI or CODX more profitable?

Zynex has a net margin of -68.35% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets Zynex -68.35% -804.30% -36.67% Co-Diagnostics -6,760.63% -164.92% -141.15%

Do analysts rate OSRH or ZYXI?

Zynex has a consensus target price of $4.90, suggesting a potential upside of 3,820.00%. Given Zynex's stronger consensus rating and higher possible upside, analysts plainly believe Zynex is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zynex 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, OSRH or ZYXI?

Zynex has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OSR $2.63M 4.71 -$27.06M -$0.33 N/A Zynex $108.20M 0.04 $2.99M -$2.43 N/A

Is OSRH or ZYXI more profitable?

Zynex has a net margin of -68.35% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets OSR -363.26% -7.24% -5.41% Zynex -68.35% -804.30% -36.67%

Which has better valuation and earnings, ZYXI or ICU?

Zynex has higher revenue and earnings than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A SeaStar Medical $1.44M 8.91 -$12.15M -$4.80 N/A

Is ZYXI or ICU more profitable?

Zynex has a net margin of -68.35% compared to SeaStar Medical's net margin of -828.62%. SeaStar Medical's return on equity of -146.29% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets Zynex -68.35% -804.30% -36.67% SeaStar Medical -828.62% -146.29% -96.48%

Which has better earnings and valuation, ZYXI or FEMY?

Zynex has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A Femasys $2.38M 4.95 -$18.63M -$5.40 N/A

Is ZYXI or FEMY more profitable?

Zynex has a net margin of -68.35% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets Zynex -68.35% -804.30% -36.67% Femasys -521.97% -258.08% -73.72%

Which has stronger valuation and earnings, SURG or ZYXI?

Zynex has higher revenue and earnings than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SurgePays $62.37M 0.16 -$36.07M -$1.94 N/A Zynex $108.20M 0.04 $2.99M -$2.43 N/A

Is SURG or ZYXI more profitable?

SurgePays has a net margin of -64.91% compared to Zynex's net margin of -68.35%. Zynex's return on equity of -804.30% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% Zynex -68.35% -804.30% -36.67%

Zynex (ZYXI) Competitors

$0.12 0.00 (0.00%)

As of 06/23/2026

Compare

ZYXI vs. CODX, OSRH, ICU, FEMY, and SURG

Should you buy Zynex stock or one of its competitors? MarketBeat compares Zynex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zynex include Co-Diagnostics (CODX), OSR (OSRH), SeaStar Medical (ICU), Femasys (FEMY), and SurgePays (SURG). These companies are all part of the "medical equipment" industry.

How does Zynex compare to Co-Diagnostics?

Zynex (NASDAQ:ZYXI) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

29.7% of Zynex shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 49.3% of Zynex shares are owned by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Zynex has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market.

Zynex presently has a consensus target price of $4.90, suggesting a potential upside of 3,820.00%. Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 1,933.75%. Given Zynex's higher possible upside, analysts plainly believe Zynex is more favorable than Co-Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Zynex's average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score.

Company	Overall Sentiment
Zynex	Neutral
Co-Diagnostics	Neutral

Zynex has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
Co-Diagnostics	$620K	19.75	-$46.90M	-$15.77	N/A

Zynex has a net margin of -68.35% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

Summary

Zynex beats Co-Diagnostics on 9 of the 12 factors compared between the two stocks.

How does Zynex compare to OSR?

OSR (NASDAQ:OSRH) and Zynex (NASDAQ:ZYXI) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Zynex has a net margin of -68.35% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-363.26%	-7.24%	-5.41%
Zynex	-68.35%	-804.30%	-36.67%

Zynex has a consensus target price of $4.90, suggesting a potential upside of 3,820.00%. Given Zynex's stronger consensus rating and higher possible upside, analysts plainly believe Zynex is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

55.3% of OSR shares are held by institutional investors. Comparatively, 29.7% of Zynex shares are held by institutional investors. 36.8% of OSR shares are held by company insiders. Comparatively, 49.3% of Zynex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

OSR has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Zynex has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

Zynex has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.63M	4.71	-$27.06M	-$0.33	N/A
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A

In the previous week, OSR had 1 more articles in the media than Zynex. MarketBeat recorded 1 mentions for OSR and 0 mentions for Zynex. OSR's average media sentiment score of 0.51 beat Zynex's score of 0.00 indicating that OSR is being referred to more favorably in the media.

Company	Overall Sentiment
OSR	Positive
Zynex	Neutral

Summary

Zynex beats OSR on 9 of the 16 factors compared between the two stocks.

How does Zynex compare to SeaStar Medical?

Zynex (NASDAQ:ZYXI) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Zynex has a net margin of -68.35% compared to SeaStar Medical's net margin of -828.62%. SeaStar Medical's return on equity of -146.29% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
SeaStar Medical	-828.62%	-146.29%	-96.48%

Zynex has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.05, indicating that its stock price is 205% less volatile than the broader market.

29.7% of Zynex shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 49.3% of Zynex shares are owned by company insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zynex has higher revenue and earnings than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
SeaStar Medical	$1.44M	8.91	-$12.15M	-$4.80	N/A

In the previous week, SeaStar Medical had 3 more articles in the media than Zynex. MarketBeat recorded 3 mentions for SeaStar Medical and 0 mentions for Zynex. Zynex's average media sentiment score of 0.00 equaled SeaStar Medical'saverage media sentiment score.

Company	Overall Sentiment
Zynex	Neutral
SeaStar Medical	Neutral

Zynex currently has a consensus price target of $4.90, indicating a potential upside of 3,820.00%. SeaStar Medical has a consensus price target of $8.00, indicating a potential upside of 150.00%. Given Zynex's higher probable upside, equities research analysts clearly believe Zynex is more favorable than SeaStar Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Zynex beats SeaStar Medical on 10 of the 13 factors compared between the two stocks.

How does Zynex compare to Femasys?

Zynex (NASDAQ:ZYXI) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Zynex presently has a consensus target price of $4.90, indicating a potential upside of 3,820.00%. Femasys has a consensus target price of $106.67, indicating a potential upside of 2,638.55%. Given Zynex's higher possible upside, analysts clearly believe Zynex is more favorable than Femasys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zynex has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
Femasys	$2.38M	4.95	-$18.63M	-$5.40	N/A

Zynex has a net margin of -68.35% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
Femasys	-521.97%	-258.08%	-73.72%

Zynex has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Femasys has a beta of -2.23, indicating that its share price is 323% less volatile than the broader market.

29.7% of Zynex shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 49.3% of Zynex shares are owned by company insiders. Comparatively, 7.8% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Femasys had 2 more articles in the media than Zynex. MarketBeat recorded 2 mentions for Femasys and 0 mentions for Zynex. Zynex's average media sentiment score of 0.00 equaled Femasys'average media sentiment score.

Company	Overall Sentiment
Zynex	Neutral
Femasys	Neutral

Summary

Zynex beats Femasys on 9 of the 15 factors compared between the two stocks.

How does Zynex compare to SurgePays?

SurgePays (NASDAQ:SURG) and Zynex (NASDAQ:ZYXI) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

SurgePays has a net margin of -64.91% compared to Zynex's net margin of -68.35%. Zynex's return on equity of -804.30% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
Zynex	-68.35%	-804.30%	-36.67%

In the previous week, SurgePays had 2 more articles in the media than Zynex. MarketBeat recorded 2 mentions for SurgePays and 0 mentions for Zynex. SurgePays' average media sentiment score of 1.15 beat Zynex's score of 0.00 indicating that SurgePays is being referred to more favorably in the media.

Company	Overall Sentiment
SurgePays	Positive
Zynex	Neutral

Zynex has higher revenue and earnings than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$62.37M	0.16	-$36.07M	-$1.94	N/A
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 29.1% of SurgePays shares are owned by insiders. Comparatively, 49.3% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

SurgePays has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Zynex has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

SurgePays currently has a consensus target price of $3.50, indicating a potential upside of 768.49%. Zynex has a consensus target price of $4.90, indicating a potential upside of 3,820.00%. Given Zynex's stronger consensus rating and higher possible upside, analysts plainly believe Zynex is more favorable than SurgePays.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Zynex beats SurgePays on 10 of the 15 factors compared between the two stocks.

Get Zynex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYXI vs. The Competition

Export

Metric	Zynex	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.80M	$8.14B	$6.55B	$12.21B
Dividend Yield	N/A	2.59%	2.69%	5.83%
P/E Ratio	-0.05	14.99	24.98	24.15
Price / Sales	0.04	6.96	550.37	122.48
Price / Cash	0.51	16.83	44.82	54.51
Price / Book	0.11	3.29	10.79	6.51
Net Income	$2.99M	$226.25M	$3.56B	$337.14M
7 Day Performance	N/A	-0.76%	1.94%	0.21%
1 Month Performance	N/A	-2.58%	1.39%	1.17%
1 Year Performance	-95.00%	0.18%	31.08%	28.90%

Zynex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYXI Zynex	N/A	$0.13 flat	$4.90 +3,820.0%	N/A	$3.80M	$108.20M	N/A	770
CODX Co-Diagnostics	1.7444 of 5 stars	$3.84 +1.6%	$67.50 +1,657.8%	-57.8%	$14.18M	$620K	N/A	100	Gap Down
OSRH OSR	1.0442 of 5 stars	$0.38 -0.2%	N/A	-72.4%	$13.48M	$2.91M	N/A	N/A
ICU SeaStar Medical	2.2877 of 5 stars	$3.05 -2.7%	$8.00 +162.7%	+3.6%	$12.18M	$1.23M	N/A	2	News Coverage
FEMY Femasys	1.5118 of 5 stars	$3.83 -3.7%	$106.67 +2,684.3%	-77.7%	$11.69M	$2.29M	N/A	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYXI) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zynex (ZYXI) Competitors

ZYXI vs. CODX, OSRH, ICU, FEMY, and SURG

How does Zynex compare to Co-Diagnostics?

Summary

How does Zynex compare to OSR?

Summary

How does Zynex compare to SeaStar Medical?

Summary

How does Zynex compare to Femasys?

Summary

How does Zynex compare to SurgePays?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYXI vs. The Competition

Zynex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zynex (ZYXI) Competitors

ZYXI vs. CODX, OSRH, ICU, FEMY, and SURG

How does Zynex compare to Co-Diagnostics?

Do insiders and institutionals have more ownership in ZYXI or CODX?

Which has more volatility & risk, ZYXI or CODX?

Do analysts rate ZYXI or CODX?

Does the media refer more to ZYXI or CODX?

Which has higher earnings & valuation, ZYXI or CODX?

Is ZYXI or CODX more profitable?

Summary

How does Zynex compare to OSR?

Is OSRH or ZYXI more profitable?

Do analysts rate OSRH or ZYXI?

Do institutionals & insiders believe in OSRH or ZYXI?

Which has more volatility and risk, OSRH or ZYXI?

Which has stronger earnings and valuation, OSRH or ZYXI?

Does the media prefer OSRH or ZYXI?

Summary

How does Zynex compare to SeaStar Medical?

Is ZYXI or ICU more profitable?

Which has more risk and volatility, ZYXI or ICU?

Do insiders & institutionals believe in ZYXI or ICU?

Which has better valuation and earnings, ZYXI or ICU?

Does the media favor ZYXI or ICU?

Do analysts recommend ZYXI or ICU?

Summary

How does Zynex compare to Femasys?

Do analysts recommend ZYXI or FEMY?

Which has better earnings and valuation, ZYXI or FEMY?

Is ZYXI or FEMY more profitable?

Which has more volatility & risk, ZYXI or FEMY?

Do insiders and institutionals have more ownership in ZYXI or FEMY?

Does the media favor ZYXI or FEMY?

Summary

How does Zynex compare to SurgePays?

Is SURG or ZYXI more profitable?

Does the media refer more to SURG or ZYXI?

Which has stronger valuation and earnings, SURG or ZYXI?

Do institutionals and insiders have more ownership in SURG or ZYXI?

Which has more volatility & risk, SURG or ZYXI?

Do analysts rate SURG or ZYXI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYXI vs. The Competition

Zynex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools